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Abstract
Objectives—We evaluated the use of treponemal serum tests in cerebrospinal fluid (CSF) to 
diagnose neurosyphilis since CSF–Venereal Disease Research Laboratory (VDRL) is specific but 
lacks sensitivity.
Methods—We tested CSF specimens using the following treponemal serum tests: INNO-LIA, 
Treponema pallidum particle agglutination (TP-PA), Trep-Sure, and Maxi-Syph. The reference 
standard to calculate sensitivity and specificity was having two or more reactive/positive tests on 
CSF.
Results—The reference standard group included 11 cases that fulfilled the definition of 
neurosyphilis (reactive CSF-VDRL plus symptoms) and three cases that did not fulfill the 
definition: two cases had neurologic symptoms but a nonreactive CSF-VDRL, and one had several 
positive CSF syphilis tests (reactive VDRL and positive treponemal and syphilis polymerase chain 
reaction) but no history (referred sample). Controls included 18 patients in whom a CSF-VDRL 
was performed the same week as patients in the reference group. The sensitivity was 85.7% 
(12/14) for CSF-VDRL, 92.9% (13/14) for Trep-Sure, 100% (10/10) for Maxi-Syph, 92.3% 
(12/13) for INNO-LIA, and 83.3% (10/12) for TP-PA. Specificity was 100% for all tests.
Conclusions—Treponemal serum tests performed on CSF were useful in identifying two 
patients with nonreactive CSF-VDRL.
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Clinical diagnosis of neurosyphilis is challenging since patient presentation varies. Persons 
with clinical signs of neurosyphilis (eg, cranial nerve dysfunction, auditory or ophthalmic 
abnormalities, loss of vibration sense, altered mental status, meningitis, and stroke) warrant 
further laboratory investigation. Although no single laboratory test can be used to diagnose 
neurosyphilis, a variety of laboratory parameters in cerebrospinal fluid (CSF) can aid in the 
diagnosis, yet there are caveats in different patient groups1 and those coinfected with human 
immunodeficiency virus (HIV).2 A definitive diagnosis of neurosyphilis can be performed 
by identifying Treponema pallidum in CSF by polymerase chain reaction (PCR), detecting 
treponemes in brain tissue by silver staining, immunohistochemistry, or direct fluorescent 
antiNormal, but these test modalities and samples are not available in many clinical settings.
In a person with neurologic signs or symptoms, a reactive CSF–Venereal Disease Research 
Laboratory (VDRL) (in a specimen not contaminated with blood) is considered diagnostic of 
neurosyphilis, while probable cases include patients with clinical signs suggestive of 
neurosyphilis or suggestive of other syphilis stages with negative CSF-VDRL but reactive 
serologic treponemal and nontreponemal tests and alterations in the CSF protein or 
leukocyte counts.3 Because the CSF-VDRL test has high specificity but lacks sensitivity,4 
serum T pallidum–specific or treponemal tests such as T pallidum particle agglutination 
(TP-PA) or fluorescent treponemal antiNormal absorption (FTA-ABS) have been used to test 
CSF to improve neurosyphilis diagnosis.5-9 However, TP-PA and FTA-ABS are manual tests 
performed in reference laboratories, and their use in serum has been supplanted by 
treponemal enzyme immunosorbent assays (EIAs) and chemiluminescent immunoassays 
(CIAs), which are automated and interfaced to electronic medical records.10 When using 
serum, the agreement of treponemal EIAs and CIAs with FTA-ABS is above 95%.11 Added 
advantages of using automated instrumentation to detect treponemal-specific antibodies on 
CSF specimens include requiring low specimen volume and quick turnaround time. The goal 
of this study was to evaluate the use of serum treponemal immunoassays on CSF specimens 
and define their potential use for diagnosis of neurosyphilis.
Materials and Methods
Specimen Selection
Twelve VDRL-positive CSF specimens were collected from January 2011 to May 2013 after 
routine testing had been completed in one laboratory from a two-hospital system. One or 
two VDRL-negative CSF specimens that were tested in the same laboratory during the same 
week when a CSF-VDRL–positive sample occurred were included as controls. CSF 
specimens were refrigerated prior to batch testing with VDRL and subsequently frozen at 
−20°C. Except for the CSF-VDRL test, all other syphilis tests were performed at the Centers 
for Disease Control and Prevention (CDC), Atlanta, Georgia, with spent CSF samples 
(remaining sample after other diagnostic tests were performed), and thus the volume varied 
and not all tests could be performed in some cases.
Chart Review
Patients’ charts were reviewed and the following information was extracted: age; sex; 
neurologic signs and symptoms; rapid plasma reagin (RPR) test result; HIV status, including 
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CD4 cell count; and viral load when available. We also captured specific treatment for 
neurosyphilis with intravenous penicillin. Completeness of clinical information varied since 
some specimens were referred by other institutions. The study protocol was reviewed and 
approved by institutional review boards at Emory University and the CDC.
Tests Performed on CSF
The VDRL test was performed according to the manufacturer’s instructions (Becton-
Dickinson, Sparks, MD). Reactive specimens were titered by preparing twofold dilutions of 
each sample. The CSF-VDRL test is a nontreponemal test that measures antilipid (mostly 
cardiolipin) antibodies that appear as a result of T pallidum infection.
The Trep-Sure (Trinity Biotech, Bray, Ireland) and Maxi-Syph (Sire Diagnostics, Oakville, 
Ontario, Canada) EIAs were performed according to the manufacturers’ instructions. Both 
tests use a microtiter plate coated with highly purified specific T pallidum antigen and 
measure both IgG and IgM antitreponemal antibodies. EIA plates were read on a FLUOstar 
Omega microplate reader (BMG Labtech, Ortenburg, Germany). Results were reported 
based on the serum sample’s index value, which was calculated by dividing the sample’s 
optical density by the cutoff value. A specimen was considered nonreactive if the index 
value was less than 0.8 and reactive if more than 1.2, while in-between values were 
considered equivocal.
The INNO-LIA Syphilis Score test was performed using the AUTO-LIA 48 automated 
system according to the manufacturer’s instructions (Innogenetics N.V., Gent, Belgium). 
INNO-LIA is a line immunoassay that tests for IgG and IgM antibodies against specific 
treponemal antigens, three recombinant proteins (TpN47, TpN17, and TpN15), and a 
synthetic peptide (TmpA). Samples and controls are placed on the paper strip containing the 
antigens. Detection of an antigen/antiNormal reaction is done by using an enzymatic 
reaction. A specimen is considered positive if reactivity is observed with at least two of the 
four antigens.
The Serodia–TP-PA test (Fujirebio America, Fairfield, NJ) was performed according to the 
manufacturer’s instructions. Gelatin particles coated with purified T pallidum organisms will 
agglutinate with anti–T pallidum antibodies in a patient’s serum, indicating the presence of 
IgG and IgM antitreponemal antibodies.
DNA was extracted from 200 μL and 400 μL for each patient’s CSF sample per the 
manufacturer’s instructions using the QIAamp DNA mini kit (Qiagen, Valencia, CA). Both 
DNA samples were eluted for a total volume of 50 μL. DNA samples were tested with real-
time duplex PCR targeting the DNA polymerase I gene (polA, tp0105) of T pallidum and a 
PCR inhibition control targeting the human ribonuclease P gene. PCR amplification was 
performed in a 50-μL reaction using 20 μL of the DNA sample. The PCR reaction mixture 
contained 300 nmol/L sense primer (CAGGATCCGGCATATGTCC), 300 nmol/L antisense 
primer (AAGTGTGAGCGTCTCATCATTCC), and 200 nmol/L TaqMan probe (CalRed610-
CTGTCATGCAC-CAGCTTCGACGTCTT–black hole quencher 3 [BHQ3]) for polA 
detection, as well as 80 nmol/L sense primer (CCAAGTGTGAGGGCTGAAAAG), 80 
nmol/L antisense primer (TGTTGTGGCTGATGAACTATAAAAGG), and 80 nmol/L 
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TaqMan probe (Cy5-CCCCA GTCTCTGTCAG-CACTCCCTTC-BHQ3) for human 
ribonuclease P gene detection; 1× PCR buffer; 5 mmol/L MgCl2; 200 μmol/L each dATP, 
dGTP, dCTP, and dUTP; 1 unit of uracil-N-gly-cosylase; and 2 units of AmpliTaq Gold 
DNA polymerase (Applied Biosystems, Carlsbad, CA). Appropriate positive- and negative-
template controls were included in the run. PCR amplification was done in a Rotor-Gene 
6000 real-time PCR instrument (Qiagen, Germantown, MD) using the following conditions: 
hold cycles at 50°C for 2 minutes and 95°C for 10 minutes, followed by 50 PCR cycles at 
95°C for 20 seconds and 60°C for 1 minute.
As part of the patients’ diagnostic workup, CSF cellularity, protein and glucose 
concentration, and tests to rule out other causes of meningitis or encephalitis were 
performed on CSF specimens from these patients.
Statistical Analysis
To calculate sensitivity, specificity, and positive and negative predictive values, we divided 
patients into two groups; those who had two or more reactive/positive treponemal, 
nontreponemal, or PCR tests in CSF were considered the reference (gold) standard, while 
other patients were considered controls. Comparison of these two groups for age and CSF 
values regarding cellularity and glucose and protein concentration was performed using a 
two-tailed, unpaired t test using the online QuickCalks (GraphPad Software, La Jolla, CA).
Results
A total of 32 CSF specimens were tested. The mean age of the patients was 50 years, 
including 10 women and 22 men. Thirty patients had neurologic signs and symptoms. 
Patients without neurologic symptoms included a 53-year-old HIV-positive man who had a 
fever and a sample from a 49-year-old man who was referred for testing. Of the 30 
symptomatic patients, 12 had HIV infection; 10 of 12 patients had a CD4 cell count 
available at the time the CSF specimen was obtained, with a mean CD4 cell count of 268 
(range, 8-642). In three of the 12 HIV-infected patients, a viral load was available; it was less 
than 20 in one patient, and the other two had uncontrolled viremia (>57,000). Two HIV-
infected persons had hepatitis C.
Fourteen of 32 patients were considered in the reference group; 11 fulfilled the definition of 
having neurosyphilis, while three did not. The cases that did not fulfill the definition 
included a 41-year-old man with neurologic symptoms (decreased hearing, tinnitus, and loss 
of vision) and a positive RPR but negative CSF-VDRL. A 49-year-old man whose specimen 
was referred for testing (no clinical information was available) had a reactive CSF-VDRL, 
positive treponemal tests in CSF, and a positive PCR in CSF. The last patient in the gray 
zone was a 50-year-old HIV-positive woman who had altered mental status, nausea, 
vomiting, and diarrhea; did not have a serum RPR performed, although she had increased 
CSF protein and lymphocytes; and was diagnosed as having a stroke. This patient had 
antisyphilis antibodies detected by the serum tests in CSF, suggesting that she had syphilis, 
particularly since she frequented the emergency department but refused care.
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The mean age for the reference group was 43 (range, 25-56) years, and the mean age for the 
control group was 53 (range, 18-89) years (P = .037). Table 1 presents in aggregate the 
clinical and laboratory characteristics of patients in the reference and control groups. The 
diagnoses of the 18 controls included neoplasias, stroke, autoimmune disease (multiple 
sclerosis), suspected viral encephalitis, and diabetes with encephalopathy. RPR was 
performed on serum in 10 of the 14 patients in the reference group and in five of 18 controls. 
The serum RPR was reactive with titers ranging from 1:32 to 1:512 in nine patients in the 
reference group. The patient with the reactive serum RPR in the control group had a titer of 
1:4 and was considered as having a false-positive result since an enzyme-linked 
immunosorbent assay syphilis antiNormal test was negative in the setting of a stroke 
(nonreactive CSF-VDRL and no CSF WBCs).
Appropriate treatment for neurosyphilis with intravenous penicillin was documented in 10 of 
the 14 patients in the reference group. For those patients in whom treatment of neurosyphilis 
was not documented, one was referred to his primary care physician for treatment, and two 
patients were noncompliant with treatment; the last treatment is unknown since the CSF 
specimen was a referral. None of the patients in the control group were treated for syphilis 
or neurosyphilis.
Patients in the reference group had lower CSF glucose (54 mg/dL; range, 36-66 mg/dL) 
compared with controls (mean, 76 mg/dL; range, 53-175 mg/dL) (P = .029) and higher 
protein (mean, 99 mg/dL; range, 35-300 mg/dL) compared with controls (mean, 42 mg/dL; 
range, 18-100 mg/dL) (P = .025). The increased WBC count became statistically significant 
between the groups (P < .05) once the patient with carcinomatosis was excluded (since all 
cells present in CSF were malignant rather than inflammatory). The mean number of white 
blood cells was 17/μL (range, 0-76/μL) in the reference group and 3/μL (range, 0-27/μL) the 
control group. In the reference group, 12 (92%) of 13 patients had a predominance of 
lymphocytes in CSF, while this occurred in only eight (57%) of 14 controls. None of the 
CSF specimens was bloody.
Table 2 shows the results of syphilis tests performed on CSF from both groups. CSF-VDRL 
was reactive in 12 (85.7%) of 14 patients in the reference group, with titers ranging from 1:1 
to 1:32. None of the patients in the control group had a positive CSF-VDRL test. Trep-Sure 
was performed on all 32 specimens, INNO-LIA on 31, TP-PA on 30, and Maxi-Syph on 28. 
Of the 14 patients in the reference group, 13 CSF samples tested positive by Trep-Sure, 
including two patients who were CSF-VDRL nonreactive; 10 of 12 tested were positive by 
TP-PA; 12 of 13 by INNO-LIA; 10 of 10 by Maxi-Syph; and 2 of 10 by PCR. Reextraction 
and concentration of DNA from CSF did not yield any additional positives by PCR.
Of the two patients with nonreactive VDRL but reactive Trep-Sure specimens, one was the 
41-year-old HIV-positive man with possible neurosyphilis who had tinnitus and loss of 
vision and also had reactive CSF with TP-PA, INNO-LIA, and Maxi-Syph. The other patient 
was a 50-year-old woman with HIV infection who had a cerebrovascular accident and whose 
CSF tested positive by the Maxi-Syph EIA.
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The CSF-VDRL missed two patients in the reference group, giving a sensitivity of 85.7% a 
specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 
89.5%. One patient in the reference group tested negative by Trep-Sure EIA, giving a test 
sensitivity of 92.9%, a specificity of 100%, a positive predictive value of 100%, and a 
negative predictive value of 94.7%. All 10 samples tested were reactive by the Maxi-Syph 
EIA, giving 100% sensitivity, specificity, and positive and negative predictive values. As 
with Trep-Sure, INNO-LIA missed one patient in the reference group, giving a sensitivity of 
92.3%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive 
value of 94.7%. The TP-PA missed two patients in the reference group, giving a sensitivity 
of 83.3%, a specificity of 100%, a positive predictive value of 100%, and a negative 
predictive value of 90%.
Discussion
Our results indicate that Trep-Sure, Maxi-Syph EIA, TP-PA, and INNO-LIA performed on 
CSF could be useful for the diagnosis of neurosyphilis when the CSF-VDRL is nonreactive, 
which is particularly problematic in patients with asymptomatic neurosyphilis who are 
coinfected with HIV.2,3,12,13 In our evaluation, there were three probable cases of 
neurosyphilis, including two HIV-positive patients with negative CSF-VDRL. One patient 
had decreased hearing, tinnitus, and loss of vision, and all treponemal tests on CSF were 
positive, while the other patient had altered mental status and a cerebrovascular event with 
only positive EIA treponemal tests on CSF. Our data suggest that it may be useful to perform 
treponemal tests in CSF of HIV-positive patients when the CSF-VDRL is nonreactive but 
neurosyphilis is suspected.
Treponemal tests performed on CSF showed good sensitivity and specificity in our study. 
Previous studies using treponemal tests on CSF specimens have primarily used FTA, FTA-
ABS, TP-PA, and a T pallidum hemagglutination assay.14-19 A systematic review of these 
publications showed that the performance was difficult to assess due to the heterogeneity of 
the populations tested and the methods used to assess diagnosis.20 Recently, INNO-LIA has 
been used in CSF specimens, although the authors advocate the use of an IgG and IgM 
serum CSF index to define central nervous system involvement.19,21 It should be noted that 
when serum CSF indexes are proposed for diagnoses of a variety of conditions, obtaining the 
serum specimen may be neglected, leading to lack of usage of these indexes. Publications 
regarding performance and use of Trep-Sure and the INNO-LIA assay are available for 
serum, showing good sensitivity and specificity.11,21-24
Consideration should be given to the possibility of the passage of antisyphilis IgG antibodies 
from serum to CSF when using serum treponemal tests for the evaluation of CSF 
infection.25 Although we did not address this question, one of the patients in the reference 
group had a negative CSF-VDRL with a reactive RPR of 1:128, lymphocytic pleocytosis, 
and reactive treponemal tests, which likely indicate central nervous system involvement; 
however, a breach in the blood-brain barrier cannot be ruled out. On the other hand, one 
could argue that if treponemal tests in CSF are positive because of the passage of antibodies 
through the blood-brain barrier, both cases in this series with nonreactive CSF-VDRL should 
be considered to have possible neurosyphilis.
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PCR positivity in our study was lower than the 25% to 60% range reported in other 
studies.9,25,26 Reported sensitivity for PCR performed in swabs of primary and secondary 
syphilitic lesions is 82%, with a specificity of 95%, compared with dark-field microscopy. 
When performing PCR on plasma or serum, the sensitivity decreases to around 16% and is 
lower in the later stages of syphilis, suggesting there are few treponemes circulating in 
peripheral blood.27 Freeze-drying CSF concentrates the sample and improves PCR 
sensitivity.25 Currently, the utility of CSF PCR to detect T pallidum is not well established 
since the presence of DNA does not necessarily indicate disease activity but the residual 
presence of nucleic acids.28 The low PCR-positive rate observed in our study can be 
attributed to using CSF specimens that had been refrigerated rather than frozen immediately.
There are several limitations to this study. Clinical information was retrospective, and 
control group specimens were selected randomly so not all clinical parameters were 
available. Not all tests could be performed in each sample because we used spent samples 
and the volume varied. Last, the conformation of the reference group requiring two or more 
reactive/positive treponemal, nontreponemal, or PCR CSF tests likely increased the 
calculation of sensitivity and specificity. Of the patients included in the reference group, the 
50-year-old HIV-positive woman with a stroke was the only patient who could be considered 
in either group. We elected to place her in the reference group because she had antibodies 
against syphilis in CSF, which likely reflect the presence of antibodies in serum, particularly 
in a patient who frequently refused care.
In summary, our study shows that serum treponemal tests performed on CSF may be useful 
to diagnose neurosyphilis where there is high clinical suspicion but the CSF-VDRL is 
nonreactive. The advantages of EIA platforms (Trep-Sure and Maxi-Syph) include the 
presence of instruments that can perform the tests in most clinical laboratories and 
technologists’ familiarity with EIAs; however, validation of the sample type will need to be 
conducted in each laboratory. Although our results are preliminary due to the small sample 
size, they support the use of an algorithm in which serum treponemal tests are performed in 
CSF specimens once clinicians communicate with the laboratory that the CSF-VDRL was 
nonreactive but the patient has signs and symptoms compatible with neurosyphilis.
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Table 1




Group (n = 14)b
Control Group
(n = 18)
Age, mean (range), y 43 (25-56) 53 (18-89)
Male sex 13 (93) 9 (50)
Symptoms
 Headache 5 (38) 5 (28)
 Visual disturbances 5 (38) 3 (17)
 Psychological disturbances 4 (31) 2 (11)
 Nausea, vomiting 4 (31) 3 (17)
 Dizziness 2 (15) 2 (11)
 Hearing problems 1 (8) 1 (6)
 Gait abnormalities 1 (8) 3 (17)
 Sleeping disturbances 1 (8) 1 (6)
 Fever 1 (8) 2 (11)
 No neurologic symptoms 1 (8) 0
 Numbness, paresthesias 0 4 (22)
 Focal neurologic signs 0 2 (11)
 Tremors 0 1 (6)
 Increased intracranial pressure 0 1 (6)
Reactive RPR, No. performed 9 of 10 1 of 5
Range of RPR titer 1:32 to 1:512 1:4
HIV positive, No. performed 11 of 12 1 of 4
HIV, human immunodeficiency virus; RPR, rapid plasma reagin.
a
Values are presented as number (%) unless otherwise indicated.
b
No clinical information is available in one specimen in the reference group since it was referred for testing.
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Table 2









 35/M R R ND ND ND ND
 43/M R R ND ND R ND
 47/M R R R R R −
 33/M R R R R R +
 49/M R NR R NR R +
 56/M R R R R R −
 32/M R R R R R −
 55/M R R R R R −
 53/M R R R R R −
 52/M R R ND R R −
 31/M R R ND R R ND
 25/M R R R R R −
 41/M NR R R R R −
 50/F NR R R NR NR −
Control group
 47/F NR NR NR NR NR −
 65/F NR NR NR NR NR −
 57/M NR NR NR NR NR −
 51/F NR NR NR NR NR −
 89/F NR NR NR NR NR −
 19/F NR NR NR NR NR −
 58/F NR NR NR NR NR −
 70/M NR NR NR NR NR −
 88/M NR NR NR NR NR −
 44/M NR NR NR NR NR −
 40/M NR NR NR NR NR −
 48/M NR NR NR NR NR −
 18/M NR NR NR NR NR −
 57/F NR NR NR NR NR −
 54/F NR NR NR NR NR −
 63/M NR NR NR NR NR −
 85/F NR NR NR NR NR −
 60/M NR NR NR NR NR −
CSF, cerebrospinal fluid; ND, not done; NR, nonreactive; PCR, polymerase chain reaction; R, reactive; TP-PA, Treponema pallidum particle 
agglutination; VDRL, Venereal Disease Research Laboratory; +, positive; −, negative.
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